Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRON vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRON Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

CRON Overall Winner 6-Pillar Tally: CRON 5 – 1 TLPH Matrix Metrics: CRON 8 – 2 TLPH

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRON carries a Unified Composite Score of 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Technical & Structure Timing Caution: CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.6); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRON vs TLPH
CRON NASDAQ Head-to-Head Winner
Cronos Group Inc. Common Share
Medicinal Chemicals & Botanical Products
$3.26
-3.48% 1D
Market Cap $1.2B
TTM Revenue $206M
Forward P/E 13.3x
Beta / 30D Vol 0.35β · 40% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 46.0 Fund 51.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.6 · SMA20: $3.41 · SMA50: $3.32
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (CRON 5 – 1 TLPH)

Columns: Metric · CRON · TLPH
1. Valuation Multiples TLPH
Forward P/E 13.3x 1.0x
Trailing P/E 21.3x 1.0x
PEG Ratio N/M N/M
EV / Revenue 4.1x N/M
2. Growth & Scale CRON
Revenue Growth (YoY) +74.6% +0.0%
Earnings Growth (YoY) -44.7% +0.0%
TTM Revenue (USD) $206M $1,000
Market Cap $1.2B $53.7M
3. Profitability & Quality CRON
Gross Margin 46.3% N/A
Operating Margin 6.1% -1474700.0%
Net Profit Margin 28.0% 0.0%
Return on Equity (ROE) 6.1% -143.4%
4. Balance Sheet & Cash Flow CRON
Cash Generation (TTM) $65M -$15M EBITDA
Cash Flow Margin 31.6% N/A
Net Cash / Leverage $410M Net Cash $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRON
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 45.9% (20th %ile) 118.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CRON
OpEx & R&D Intensity 40.2% of Rev ($83M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRON (8) vs TLPH (2)
Institutional Metric CRON TLPH Criterion Row Edge
Market Capitalization
Scale
$1.2B $53.7M Larger Scale CRON
Trailing P/E Ratio
Valuation
21.3x 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
13.3x 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+74.6% +0.0% Higher Growth CRON
Operating Margin (TTM)
Profitability
6.1% -1474700.0% Higher Margin CRON
Net Profit Margin
Profitability
28.0% 0.0% Higher Margin CRON
Return on Equity (ROE)
Capital Efficiency
6.1% -143.4% Higher ROE CRON
52-Week Range Position
Momentum
60% ($2–$4) 20% ($1–$2) Stronger Trend CRON
Beta / 30D Volatility
Risk Regime
0.35β · 40% Vol 1.11β · 58% Vol Lower Realized Risk CRON
Unified Institutional Score
Composite Signal
53.9 / 100 (HOLD) 37.1 / 100 (SELL) Higher Composite CRON
Trailing 12M Revenue (USD)
Operating Scale
$206M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$65M ($410M Net Cash) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRON +21.92 pp
CRON: +1.63% · TLPH: -20.29%
3M Horizon CRON +30.48 pp
CRON: +1.63% · TLPH: -28.85%
6M Horizon CRON +16.54 pp
CRON: +24.52% · TLPH: +7.98%
1Y Horizon CRON +49.56 pp
CRON: +31.55% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRON vs TLPH. Trailing 12-month operating profitability (CRON 6.1% vs TLPH -1474700.0%) and valuation multiples (CRON 13.3x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

CRON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$206M
Gross Margin46.3%
Op. Margin6.1%
ROE / Fwd P/E6.1% · 13.3x
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRON CONSOLIDATION
57d in phase · OBV NEUTRAL
Current IV 45.9%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRON Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and 6.1% operating margin.
OpEx & R&D Reinvestment 40.2% of Rev ($83M)
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRON vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRON carries a Unified Composite Score of 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Technical & Structure Timing Caution: CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.6); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRON leads the Growth & Scale pillar: CRON posts +74.6% YoY revenue growth and -44.7% YoY earnings growth on $206M TTM revenue (46.3% gross margin, 6.1% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, CRON generates $206M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, CRON deploys 40.2% of Rev ($83M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. CRON trades at 13.3x Forward P/E, 21.3x Trailing P/E, N/M PEG, and 4.1x EV/Revenue (31.6% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRON (6.1% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CRON carries 45.9% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 40% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.